Prof Hartmut J. Ehrlich | Chief Executive Officer
ABIVAX

Prof Hartmut J. Ehrlich, Chief Executive Officer, ABIVAX

Physician and entrepreneur with >30 years in the bio-pharmaceutical industry, 25 of which in product development at Sandoz (now Novartis) and Baxter. Focus was on pre- and post-licensing development of biologics, i.e. therapeutic proteins and vaccines.
 
Lived and worked in the US, The Netherlands, Germany, Switzerland, Austria and France.
 
Current role: CEO of ABIVAX (since 12/2013), a clinical stage biotech company targeting the immune system to eliminate life-threatening viral (e.g. HIV, Chikungunya, Dengue and Ebola), as well as inflammatory diseases. In June 2015, I led ABIVAX to the most successful Biotech IPO in France ever by raising 57.7 Mio Euro at Euronext Paris. ABIVAX’ lead compound is in Phase II clinical trials with the goal to provide a functional cure for HIV/AIDS.
 
Previous leadership roles: VP and Head of Global R&D and Medical Affairs, Baxter BioScience (2006-2013), reporting directly to the President of BioScience. Since 2006 also served as Senior Resident Manager of Baxter's Austrian sites (>4300 employees).
 
Drove the global regulatory approval of  >10 biologics in the areas Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines.
 
Served as Baxter’s principal investigator on a grant from US DHHS (BARDA), which paid $ 242 Mio (2006 – 2013) for the development of cell-culture derived seasonal and pandemic influenza vaccines.
 
Authored and coauthored >120 peer-reviewed articles and book chapters, incl. a first authorship in NEJM and a senior authorship in The Lancet.

back to speakers